1-10 of 10
Srdan Verstovsek, M.D.;PhD.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.
Journal: Blood
Blood (2006) 108 (11): 2612.
https://doi.org/10.1182/blood.V108.11.2612.2612
Published: 2006
Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 2705.
https://doi.org/10.1182/blood.V108.11.2705.2705
Published: 2006
Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 2706.
https://doi.org/10.1182/blood.V108.11.2706.2706
Published: 2006
Journal Articles

WP1066 Inhibits Growth of Human Cells Carrying the JAK2 V617F Mutation.

Taghi Manshouri, PhD, Zeev Estrov, M.D., Alfonso Quintas-Cardama, M.D., Jorge Cortes, M.D., Francis Giles, M.D., David Harris, MS, Waldemar Priebe, PhD;MS, Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD.
Journal: Blood
Blood (2006) 108 (11): 4885.
https://doi.org/10.1182/blood.V108.11.4885.4885
Published: 2006
Journal Articles

Interferon Therapy Is Predictive Factor for Improved Survival in Patients with Essential Thrombocythemia (ET).

Elias Jabbour, MD, Antoine Harb, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Sherry Pierce, BSN.BA, Jianqin Shan, Zeev Estrov, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4897.
https://doi.org/10.1182/blood.V108.11.4897.4897
Published: 2006
Journal Articles

Alemtuzumab (CAMPATH-1H ™ ) Is Effective Therapy for Hypereosinophilic Syndrome (HES).

Alfonso Quintas-Cardama, MD, Ayalew Tefferi, M.D., Jorge Cortes, M.D., Animesh Pardanani, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Pat Ault, R.N., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4902.
https://doi.org/10.1182/blood.V108.11.4902.4902
Published: 2006
Journal Articles

A Phase II Study of Oral Interferon-Alpha (IFN-a) for Patients with Essential Thrombocythemia or Polycythemia Vera.

Alfonso Quintas-Cardama, MD, Francis Giles, M.D., Jorge Cortes, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4880.
https://doi.org/10.1182/blood.V108.11.4880.4880
Published: 2006
Journal Articles

Denileukin Diftitox (Ontak™) Therapy for Patients with Systemic Mastocytosis.

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4881.
https://doi.org/10.1182/blood.V108.11.4881.4881
Published: 2006
Journal Articles

The Novel Tyrosine Kinase Inhibitor (TKI) Exel-0862 Potently Induces Apoptosis in Human FIP1L1-PDGFR-α-Expressing Cells through Caspase-Dependent Cleavage of MCL-1.

Jingpan Pan, MD, PhD, Alfonso Quintas-Cardama, M.D., Hagop Kantarjian, M.D., Peter Lamb, Ayalew Tefferi, Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4882.
https://doi.org/10.1182/blood.V108.11.4882.4882
Published: 2006
Journal Articles

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Mary Ann Richie, R.N., Gautam Borthakur, M.D., Srdan Verstovsek, M.D.;PhD
Journal: Blood
Blood (2006) 108 (11): 4884.
https://doi.org/10.1182/blood.V108.11.4884.4884
Published: 2006